• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    1/3/24 8:52:12 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 zk2430730.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934

    Seer, Inc.
    (Name of Issuer)
     
    Class A Common Stock, Par Value $0.00001 per Share

    (Title of Class of Securities)
     
    81578P106
    (CUSIP Number)

    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☐ Rule 13d-1(c)
     
    ☒ Rule 13d-1(d)
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
     


     
    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,112,235
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,112,235
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,112,235
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    6.44%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 


    Page 2 of 10 Pages

    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Co-Investment SPV I, L.P.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Cayman Islands 
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    810,961
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    810,961
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    810,961
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    1.27%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

     
    Page 3 of 10 Pages


    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon Growth Fund G.P. Limited Partnership
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    PN 

    Page 4 of 10 Pages


    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    aMoon General Partner Ltd.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    CO

    Page 5 of 10 Pages

     

    CUSIP No.
      
    81578P106
     
    1.
    Names of Reporting Persons
     
    Dr. Yair C. Schindel
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     

    4.
    Citizenship or Place of Organization

    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.
    Sole Voting Power
     
    0
    6.
     
    Shared Voting Power

    4,923,196
    7.
     
    Sole Dispositive Power
     
    0
    8.
     
    Shared Dispositive Power
     
    4,923,196
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,923,196
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    7.71%
    12.
    Type of Reporting Person (See Instructions)
     
    IN
     

    Page 6 of 10 Pages



    Item 1(a)
    Name of Issuer
     
    Seer, Inc. (the “Issuer”).
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    3800 Bridge Parkway, Suite 102, Redwood City, California 94065
     
    Item 2(a)-(b)
    Name of Person Filing; Address of Principal Business Office or, if none, Residence


    1.
    aMoon Growth Fund Limited Partnership (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    2.
    aMoon Co-Investment SPV I, L.P. (“aMoon Co-Investment”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    3.
    aMoon Growth Fund G.P. Limited Partnership (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    4.
    aMoon General Partner Ltd. (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     

    5.
    Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
     
    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. 
     
    Item 2(c)
    Citizenship
             
    aMoon is a Cayman Islands exempted limited partnership; aMoon Co-Investment is a Cayman Islands exempted limited partnership; aMoon G.P. is an Israeli limited partnership; aMoon Ltd. is an Israeli company; and Schindel is an Israeli citizen. 
     
    Item 2(d) 
    Title of Class of Securities

    Class A Common Stock, par value $0.00001 per share
     
    Item 2(e)
    CUSIP Number

    81578P106
     
    Item 3
    If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
     
    Not applicable.
     
    Item 4
    Ownership

    aMoon Growth Fund Limited Partnership


    (a)
    Amount beneficially owned:  4,112,235 shares of Class A Common Stock.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.

    Page 7 of 10 Pages


    (b)
    Percent of Class: 6.44%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,112,235 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,112,235 shares of Class A Common Stock

    aMoon Co-Investment SPV I, L.P.


    (a)
    Amount beneficially owned: 810,961 shares of Class A Common Stock.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 1.27%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 810,961 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 810,961 shares of Class A Common Stock

    aMoon Growth Fund G.P. Limited Partnership


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  aMoon G.P. is the sole general partner of aMoon and aMoon Co-Investment.  By virtue of such relationship, aMoon G.P. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    aMoon General Partner Ltd.


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  aMoon Ltd. is the sole general partner of aMoon G.P.  By virtue of such relationships, aMoon Ltd. may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.

    Page 8 of 10 Pages


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    Dr. Yair C. Schindel


    (a)
    Amount beneficially owned:  4,923,196 shares of Class A Common Stock.  Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to have shared voting and investment power with respect to the shares of Class A Common Stock of the Issuer held by aMoon and aMoon Co-Investment. Schindel disclaims beneficial ownership of the shares of Class A Common Stock of the Issuer held by aMoon, aMoon Co-Investment, aMoon G.P. and aMoon Ltd., except to the extent of his pecuniary interest therein, if any.

    All share percentage calculation are based on 63,825,213 shares of Class A Common Stock and Class B Common Stock outstanding as of November 3, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 7, 2023.


    (b)
    Percent of Class: 7.71%


    (c)
    Number of shares as to which the  person has:

    (i)
    Sole power to vote or direct the vote: 0

    (ii)
    Shared power to vote or to direct the vote: 4,923,196 shares of Class A Common Stock

    (iii)
    Sole power to dispose or to direct the disposition of: 0

    (iv)
    Shared power to dispose or to direct the disposition of: 4,923,196 shares of Class A Common Stock

    Item 5
    Ownership of Five Percent or Less of a Class

    Not applicable.
     
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
     
    Not applicable.
     
    Item 8
    Identification and Classification of Members of the Group
     
    Incorporated by reference to Items 2 and 4 of this Schedule 13G.
     
    Item 9
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10
    Certification

    Not applicable.
    Page 9 of 10 Pages

     
    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: January 3, 2024

      AMOON GROWTH FUND LIMITED PARTNERSHIP
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON CO-INVESTMENT SPV, L.P.
    BY: AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP, ITS GENERAL PARTNER
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GROWTH FUND G.P. LIMITED PARTNERSHIP
    BY:  AMOON GENERAL PARTNER LTD., ITS GENERAL PARTNER
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    AMOON GENERAL PARTNER LTD.
     
           

    By:
    /s/ Dr. Yair C. Schindel  
        Name: Dr. Yair C. Schindel  
       
    Title:   Director
     

     
    DR. YAIR C. SCHINDEL
     
           

    By:
    /s/ Dr. Yair C. Schindel  

    Page 10 of 10 Pages
    Get the next $SEER alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Achieved revenue of $4.1 million for the second quarter of 2025Launched new high-throughput Proteograph ONE assay and SP200 automation instrument, enabling previously unattainable scale and efficiencyAnnounced a collaboration with Korea University to launc

    8/6/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

    REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Seer's management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the conference. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbi

    7/31/25 4:05:54 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

    REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed,

    7/22/25 4:05:05 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by JP Morgan with a new price target

    JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

    8/11/22 6:17:02 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $13,955 worth of shares (6,827 units at $2.04), decreasing direct ownership by 2% to 436,802 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    8/21/25 4:19:37 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid sold $69,483 worth of shares (33,992 units at $2.04), decreasing direct ownership by 3% to 1,272,068 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    8/21/25 4:18:17 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Roelofs Nicolas H Phd was granted 17,083 shares, increasing direct ownership by 29% to 74,996 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    7/9/25 4:14:44 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Seer Inc.

    SCHEDULE 13G/A - Seer, Inc. (0001726445) (Subject)

    8/13/25 4:24:17 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Seer Inc.

    10-Q - Seer, Inc. (0001726445) (Filer)

    8/6/25 4:24:21 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Seer, Inc. (0001726445) (Filer)

    8/6/25 4:16:51 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

    REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

    3/16/22 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Appoints Meeta Gulyani to its Board of Directors

    REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me

    11/29/21 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Achieved revenue of $4.1 million for the second quarter of 2025Launched new high-throughput Proteograph ONE assay and SP200 automation instrument, enabling previously unattainable scale and efficiencyAnnounced a collaboration with Korea University to launc

    8/6/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

    REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer, Inc. (NASDAQ:SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed,

    7/22/25 4:05:05 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

    REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Achieved revenue of $4.2 million for the first quarter of 2025Secured a significant contract with a new customer to run a 10,000-sample study in collaboration with Discovery Life SciencesAccelerated third-party validation of platform through increasing number of customer publications, webinars, preprints and reviewsEnded the quarter with approximately $285 million of cash, cash equivalents and investments "We are proud of our

    5/13/25 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials